Conceived as far back as 2010 and formally introduced last year, POPS! involves merging hardware, software and mobile together to create a new personalized health care model for diabetic patients, their caregivers, and medical professionals.
“First and foremost, we are creating a better means for diabetics to manage their blood glucose ,” says cofounder and CEO Lonny Stormo — a former Medtronic VP, and a diabetic himself.
“And involving other stakeholders to assist in the review of ones data.”
The concept involves affixing a piece of hardware onto the back of the smartphone that can test, capture and share results on the fly. This is elaborated on in detail below at the recent MinneAnalytics HALICON conference:
“Diabetes is the leading cause of blindness, kidney failure and amputations in the US,” Stormo says. “In the big picture, there are 28 million diabetics in the US and the glucose testing market is an $11b annual market.”
His partners include Dan Davis (above), Curt Christensen, Eric Davis and Chandler Stormo.
POPS! is considered a class 2 FDA product, meaning that it does involve FDA clearance but does not require a clinical study. There are 2 patents already issued for the system and they were a finalist in the health division of the Minnesota Cup last year.